Pharmacokinetics and pharmacodynamics of antimicrobials

Clinical Infectious Diseases

Volumn 45, Issue SUPPL. 1, 2007, Pages

  Drusano, G L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL STRAIN; DRUG DOSE REDUCTION; DRUG EXPOSURE; HOSPITAL; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; REVIEW; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; RATS;

EID: 34447126309     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/518137     Document Type: Review

References (28)

1. Woodward TE, Smadel JE, Ley HL Jr. Chloramphenicol and other antibiotics in the treatment of typhoid fever and typhoid carriers. J Clin Invest 1950; 29:87-99.
2. McCrumb FR Jr, Hall HE, Imburg J, et al. Treatment of Hemophilus influenzae meningitis with chloramphenicol and other antibiotics. J Am Med Assoc 1951; 145:469-74.
3. McCrumb FR Jr, Mercier S, Robic J, et al. Chloramphenicol and terramycin in the treatment of pneumonic plague. Am J Med 1953; 14: 284-93.
4. DuPont HL, Hornick RB, Weiss CF, Snyder MJ, Woodward TE. Evaluation of chloramphenicol acid succinate therapy of induced typhoid fever and Rocky Mountain spotted fever. N Engl J Med 1970; 282:53-7.
5. Snyder MJ, Gonzalez O, Palomino C, et al. Comparative efficacy of chloramphenicol, ampicillin, and co-trimoxazole in the treatment of typhoid fever. Lancet 1976; 2:1155-7.
6. Williamson R, Tomasz A. Inhibition of cell wall synthesis and acylation of the penicillin binding proteins during prolonged exposure of growing Streptococcus pneumoniae to benzylpenicillin. Eur J Biochem 1985; 151:475-83.
7. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibiotic dosing of mice and men. Clin Infect Dis 1998; 26:1-10.
8. Eagle H, Fleischman R, Levy M. Continuous versus discontinuous therapy with penicillin: the effect of interval between injections on therapeutic efficacy. N Engl J Med 1953; 248:481-8.
9. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosing regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22:89-96.
10. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37:483-90.
11. Jumbe NL, Louie A, Miller MH, et al. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006; 50:310-7.
12. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45:2793-7.
13. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112:275-85.
14. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189:1590-7.
15. Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis 2005; 192: 420-8.
16. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-9.
17. Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1983; 11:233-8.
18. US Food and Drug Administration. Meeting of the Food and Drug Administration Advisory Committee for the Division of Anti-Infective Drug Products. 15 October 1998. Available at: http://www.fda.gov/ohrms/ dockets/ac/cder98t.htm. Accessed 15 October 1998.
19. Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for the choice of a phase II/III dose for evernimicin with application to decision support for identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001; 45:13-22.
20. Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL. An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther 1988; 44:232-8.
21. Drusano GL, Forrest A, Plaisance KI, Wade JC. A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients. Clin Pharmacol Ther 1989; 45:635-41.
22. Drusano GL. Optimal sampling theory and population modelling: application to determination of the influence of the microgravity environment on drug distribution and elimination. J Clin Pharmacol 1991; 31:962-7.
23. Drusano GL, Forrest A, Yuen JA, Plaisance KI. Optimal sampling theory: effect of error in a nominal parameter value on bias and precision of parameter estimation. J Clin Pharmacol 1994; 34:967-74.
24. Tam VH, Preston SL, Drusano GL. Optimal sampling schedule design for populations of patients. Antimicrob Agents Chemother 2003; 47: 2888-91.
25. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-81.
26. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50:425-8.
27. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43:623-9.
28. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43:1549-55.